2 Stocks Billionaires Can't Stop Buying

Billionaire investors increased exposure to Alphabet and Eli Lilly in Q2: Druckenmiller initiated a 336,300-share Alphabet position, Fisher added roughly 939,000 Alphabet shares and nearly 5% to his Lilly stake, and Griffin raised his Lilly position by 291%. Lilly represented $6.1 billion of Fisher Asset Management’s holdings at quarter-end, while Alphabet became Berkshire Hathaway’s fourth-largest holding. The article calls both stocks attractive long-term picks but cautions readers against copying investors without considering their own goals and risk tolerance.

Analysis

The billionaire-buying narrative is a weak near-term signal: reported Q2 holdings are backward-looking, do not reveal cost basis or hedges, and can reflect portfolio rebalancing rather than a fresh view. Treat the filings as attention, not a catalyst.

For Alphabet, the key debate is whether AI monetization and Cloud growth offset the risk that AI answers change the economics of search. A positive second-order outcome would be stronger Cloud demand and distribution for Gemini; the counter is higher infrastructure spending without comparable revenue, pressuring returns on capital. Microsoft and Amazon are relevant competitive benchmarks, while regulatory remedies remain a separate risk to distribution economics. Over 1–3 months, earnings evidence on Search monetization, Cloud profitability and capex matters more than investor endorsements; over 6–18 months, AI-driven changes in search behavior are the structural test.

For Lilly, investor interest does not resolve the central valuation question: whether obesity-drug demand, manufacturing capacity and payer access can support expectations as competition—especially Novo Nordisk—and additional therapies expand. Pricing or reimbursement pressure, supply constraints, or weaker persistence could reverse the thesis. Verify prescription trends, capacity ramp, payer coverage and pipeline readouts before treating position growth as confirmation. No valuation or current-price data are provided, so neither name warrants a price-specific target here.

Key Decisions for Investors

• Do not chase either stock solely on the reported filings. The information is lagged and does not establish that these investors still hold the positions or share the article’s thesis.
• GOOG: Put on an earnings watch rather than a headline-driven entry. Consider adding only if Search monetization remains resilient while Cloud growth and profitability support the AI investment; reassess if capex rises without revenue contribution or search economics materially weaken.
• LLY: Keep on a catalyst watch; before adding, verify prescription growth, production capacity, payer access and upcoming clinical data against expectations. Competitive progress from Novo Nordisk or evidence of pricing pressure would argue against the long thesis.
• No trade is supported by the supplied data alone: current valuation, earnings expectations, price action and positioning are absent. A relative-value position should wait for those inputs rather than assume billionaire holdings are an actionable signal.